Euroimmun Medizinische Labordiagnostika Ag

Mayo Foundation for Medical Education and Research

Yvonne Denno

Ramona Miske

Lars Komorowski

Madeleine Scharf

Christian Probst

Winfried Stoecker

Inga-Madeleine Dettmann

Stefanie Hahn

Stephanie Kade

Christiane Radzimski

Iswariya Venkataraman

Vanda A Lennon

Winfried Stöcker

Thomas J Kryzer

Andrew McKeon

Sean J Pittock

Waltraud Suer

Stefanie Rohwer

Bianca Teegen

Sven Meuth

Josephe A Honorat

Mandy Unger

Farid Benkhadra

George Trendelenburg

Nico Melzer

Heinz Wiendl

Fedor Heidenreich

Stephan Tiede

Ralf Gieß

Kathrin Margalene Borowski

Fedor ProfDr Heidenreich

Winfried STÖCKER

A method involves detecting in a sample an autoantibody binding specifically to a mammalian VGLUT. An autoantibody binding specifically to a mammalian VGLUT and a diagnostically useful carrier with a solid phase with an immobilized polypeptide containing a mammalian VGLUT or a variant thereof, are useful. The autoantibody can be used for diagnosing a neurological autoimmune disease or a cancer.

Method and reagents for the detection of an autoantibody

A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.

Autoantibodies to Septin-7 and diagnosis of neurological disease

The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.

Diagnosis of a neuroautoimmune disease

The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide.

Diagnosis of a neurological disease

A method is used for diagnosing a disease by detecting in a sample with antibodies from a patient an autoantibody binding to DAGLA.

Provided is a polypeptide comprising a macadamia protein running in a 2D SDS PAGE at pH 6.3 to 8.7 and 53 to 67 kDa or a protein running in a 2D SDS PAGE at pH 6.5 to 7.9 and 20 to 25 kDa or an antigenic variant thereof, and a tag for detection and/or purification, a polypeptide fused with the macadamia protein, or the macadamia protein is modified by glycosylation, phosphorylation, acetylation, decarboxylation, citrullination, or hydroxylation.

Macadamia allergen

The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient and also antibody binding to RGS8, a method for diagnosing a disease comprising the step detecting in a sample from a patient the level or activity of RGS8, a polypeptide comprising RGS8 or a variant thereof, a use of set polypeptide for the diagnosis of a disease, an antibody binding to RGS8, a use of the antibody for the diagnosis of the disease, a method for isolating an autoantibody binding to RGS8, a pharmaceutical composition or medical device comprising the polypeptide according to the present invention, a kit for the diagnosis of a disease comprising the polypeptide or the medical device according to the present invention and a use of the polypeptide, the antibody or the antibody for the manufacture of a kit or medical device.

A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.

Diagnosis of a neuroautoimmune disease comprising measuring autoantibodies to flotillin1 and/or flotillin2

Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.

Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis

Growing community of inventors

Lübeck, Germany

Yvonne Denno